Codeine Therapy and CYP2D6 Genotype
نویسنده
چکیده
The CYP2D6 enzyme metabolizes a quarter of all prescribed drugs, including codeine. Some individuals have multiple functional copies of the CYP2D6 gene, making them “ultrarapid metabolizers”. They are able to metabolize codeine to morphine more rapidly and more completely. As a result, even with normal doses of codeine, these individuals may experience the symptoms of morphine overdose, which include extreme sleepiness, confusion, and shallow breathing. Nursing mothers may also produce breast milk containing higher than expected levels of morphine that can lead to severe adverse events in their infants (1).
منابع مشابه
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity. Polymorphisms are a major cause of CYP2D6 variability. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for codeine based on CYP2D6 genotype. This documen...
متن کاملPharmacogenetics for Safe Codeine Use in Sickle Cell Disease.
After postoperative deaths in children who were prescribed codeine, several pediatric hospitals have removed it from their formularies. These deaths were attributed to atypical cytochrome P450 2D6 (CYP2D6) pharmacogenetics, which is also implicated in poor analgesic response. Because codeine is often prescribed to patients with sickle cell disease and is now the only Schedule III opioid analges...
متن کاملConsiderations for the Utility of the CPIC Guideline for CYP2D6 Genotype and Codeine Therapy.
We appreciate the recent Perspective from Nicholson and Formea (1 ) because it allows us to clarify the role of Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for clinicians. CPIC publishes genotype-based drug therapy guidelines to help clinicians understand how genetic test results could be used to optimize drug therapy. The underlying assumption for CPIC guidelines is t...
متن کاملGenetic transmission of cytochrome P450 2D6 (CYP2D6) ultrarapid metabolism: implications for breastfeeding women taking codeine.
The pro-drug codeine is commonly prescribed for postpartum pain relief in North America. The safety of codeine during breastfeeding is related in part to the extent of the active morphine metabolite catalyzed from codeine via the cytochrome P450 2D6 (CYP2D6) enzyme. In mothers who have greater than two functional copies of the CYP2D6 gene (CYP2D6 ultrarapid metabolism phenotype; UM) a substanti...
متن کاملRisk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study.
Administering codeine to breast-feeding mothers had been considered safe until the recent death of a breast-fed neonate whose mother had been prescribed codeine. We investigated the risk of opioid poisoning to breast-fed neonates using coupled physiologically based pharmacokinetic models for the mother and child. Neonatal morphine plasma concentrations were simulated for various combinations of...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2016